Intervention not reported
Interferon beta 1a‐1b No direct evidence · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…
It is very uncertain whether the intervention changes interferon beta 1a‐1b No direct evidence (very low certainty).
1 finding from 1 review
RR 1.42 [0.78, 2.6]
1 participants
Very low
Intervention not reported
Ocrelizumab No direct evidence · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention showed no clear difference in ocrelizumab No direct evidence (low certainty).
1 finding from 1 review
OR 0.82 [0.42, 1.6]
Studies not reported
Low
Intervention not reported
Ofatumumab No direct evidence · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention may leads to higher ofatumumab No direct evidence (low certainty).
1 finding from 1 review
OR 2 [1.05, 3.81]
Studies not reported
Low
Intervention not reported
Ozanimod No direct evidence · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention showed no clear difference in ozanimod No direct evidence (low certainty).
1 finding from 1 review
OR 1.01 [0.52, 1.95]
Studies not reported
Low
Intervention not reported
Ponesimod No direct evidence · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…
It is very uncertain whether the intervention changes ponesimod No direct evidence (very low certainty).
1 finding from 1 review
OR 5.04 [2.15, 11.82]
Studies not reported
Very low
Intervention not reported
Teriflunomide (Direct evidence; 2 RCTs; 2253 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention probably leads to higher teriflunomide (Direct evidence; 2 RCTs; 2253 participants) (moderate certainty).
1 finding from 1 review
Intervention not reported
Placebo · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Interferon beta‐1b (Betaferon) No direct evidence · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…
It is very uncertain whether the intervention changes interferon beta‐1b (Betaferon) No direct evidence (very low certainty).
1 finding from 1 review
RR 0.82 [0.5, 1.33]
1 participants
Very low
Intervention not reported
Interferon beta‐1a (Avonex, Rebif) (Direct evidence; 1 RCT; 560 participants) · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…
The intervention may leads to lower interferon beta‐1a (Avonex, Rebif) (Direct evidence; 1 RCT; 560… (low certainty).
1 finding from 1 review
Severe intraventricular haemorrhage · neonates with sepsis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Periventricular leukomalacia · neonates with sepsis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Length of stay among survivors · neonates with sepsis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Necrotising enterocolitis · neonates with sepsis
It is very uncertain whether pentoxifylline with antibiotics (any dose or duration) changes necrotising enterocolitis, any Bell stage compared with pentoxifylline with antibiotics and immunoglobulin M‐enriched… (very low certainty).
1 finding from 1 review
Retinopathy of prematurity · neonates with sepsis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality during hospital stay · neonates with sepsis
It is very uncertain whether pentoxifylline with antibiotics (any dose or duration) changes all‐cause mortality during hospital stay compared with immunoglobulin M‐enriched intravenous immunoglobulin with antibiotics (very low certainty).
1 finding from 1 review
Chronic lung disease in survivors · neonates with sepsis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severe intraventricular haemorrhage · neonates with sepsis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Periventricular leukomalacia · neonates with sepsis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Length of stay among survivors · neonates with sepsis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Necrotising enterocolitis · neonates with sepsis
It is very uncertain whether pentoxifylline with antibiotics (any dose or duration) changes necrotising enterocolitis, any Bell stage compared with immunoglobulin M‐enriched intravenous immunoglobulin with antibiotics (very low certainty).
1 finding from 1 review